Petra Heffeter at Medical University of Vienna - Research Interests, Publications & Academic Profile

Petra Heffeter

Full professor

Medical University of Vienna

Austria

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Turkish students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Biochemistry

40%

Pharmaceutical Chemistry

80%

Metal Chemistry

50%

Metabolic Biology

50%

Multidrug Resistance

40%

Cancer Biology

40%

Metalloenzyme

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands

Article Link

Year:

2024

Targeting PHGDH reverses the immunosuppressive phenotype of tumor-associated macrophages through α-ketoglutarate and mTORC1 signaling.

Article Link

Year:

2024

Stepwise optimization of tumor-targeted dual-action platinum(iv)-gemcitabine prodrugs

Article Link

Year:

2024

The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation

Article Link

Year:

2023

Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy.

Article Link

Year:

2023

Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100

Article Link

Year:

2023

Einbau von (Bioaktiven) Äquatorialen Liganden in Platin(IV)‐Komplexe

Article Link

Year:

2023

Insertion of (Bioactive) Equatorial Ligands into Platinum(IV) Complexes

Article Link

Year:

2023

Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer

Article Link

Year:

2023

Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo

Article Link

Year:

2023

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

Article Link

Year:

2022

The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness

Article Link

Year:

2021

CD47-targeted cancer immunogene therapy

Article Link

Year:

2021

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands

Article Link

Year:

2021

Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance

Article Link

Year:

2021

Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the <i>MGMT</i> Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set.

Article Link

Year:

2021

Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.

Article Link

Year:

2021

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake <i>in vivo</i>.

Article Link

Year:

2021

Interfering with Metabolic Profile of Triple‐Negative Breast Cancers Using Rationally Designed Metformin Prodrugs

Article Link

Year:

2021

Interfering with Metabolic Profile of Triple‐Negative Breast Cancers Using Rationally Designed Metformin Prodrugs

Article Link

Year:

2021

Collaborators16

Margit Cichna-Markl

Universität Wien

AUSTRIA

Dietmar Herndler-Brandstetter

AUSTRIA

Andreia Valente

Universidade de Aveiro

PORTUGAL

Óscar López

Associate Professor

Universidad de Sevilla

SPAIN

Thomas Mindt

Universität Wien

AUSTRIA

Maria José Villa de Brito

Assistant Professor

Faculdade de Ciências da Universidade de Lisboa

PORTUGAL

Gerwin Heller

Medical University of Vienna

AUSTRIA

Walter Berger

AUSTRIA

Amandine Moretton

Université Clermont Auvergne

FRANCE

Evelyn Rampler

Assistant Professor

Universität Wien

AUSTRIA

Hannes Lans

Associate Professor

Erasmus MC

NETHERLANDS

Maja Tomicic

Group leader/Associate Professor

University Medical Center of the Johannes Gutenberg University Mainz

GERMANY

Isabella Pötsch

Universität Wien

AUSTRIA

Manfred Ogris

Universität Wien

AUSTRIA

Samuel M. Meier‐Menches

AUSTRIA

Martin Schreiber

associate professor

Medical University of Vienna

AUSTRIA

How do Turkish students reach out?

Meet Kite AI